
Rheumatologist, A/Prof @NUSMedicine 🇸🇬 @NUHSofficial || @AIIMS_NewDelhi ‘90-‘99 🇮🇳 || #RheumTwitter🦴|| #MedEd || Mummy of 2 || Dreamer || Views my own
Singapore
Joined December 2010
- Tweets496
- Following142
- Followers201
- Likes369
And it’s a wrap for #APLAR2025
Well done team @NUHSofficial 👏🏽👏🏽
7
312
Day1 #APLAR2025
Focus on #lupus 🦋
The new TRM-SLE tinyurl.com/TRMSLE elegantly elucidated by @EricFMorand focusing on indices that alter how patients #feel, #function or #survive
And @Lupusreference very energetic talk summarising current lupus trials
Exciting times 🤩
2
174
Manjari Lahiri retweeted
Congratulations to Dr. Bhatla from the AIIMS 1990 batch. We are proud to have been her students!
@Amitvermamds @SgRheumer @SleepnLetSleep @vibhusharmamd
4-year data from TREAT EARLIER @TheLancetRheum
⬇️ risk of seronegative RA for MTX arm (& 💉 IM triamcinolone)
How about just the IM 💉 steroid ?
Somehow not really convinced that treating with MTX makes sense?
What do you think? 🤔
#RheumTwitter
thelancet.com/journals/lanrh…
1
148
Shucks 😭 didn't make it!
Oh well, keep trying💪
😂
#ACR24
Congrats to the influencers of #ACR24 & thanks for all your posts sharing knowledge from the conference!!! 🥳
@ACRheum @rheum_cat @RheumNow
@MithuRheum @EBRheum @noellealicia242 @NamrataRheum
@realcc @rheumarhyme #Rheumatology
1
273
So many options 🤩
But let's not forget that early diagnosis, close monitoring, improved adherence to treatment and minimising GC toxicity will probably have a larger impact in terms of absolute patient numbers and reach
#LupusNephritis
#Lupus
2
296
Not investing any time soon 😅 but this is a great summary!
1
164
Manjari Lahiri retweeted
💡 New hope for severe/refractory #SLE: A-319 (CD3 x CD19 TCE) shows rapid and safe immune reset!
✅ Rapid B-cell depletion, autoantibody reduction, & organ improvement by W2
✅ No CRS or ICANS observed
📊 Could this be a game-changer in SLE therapy?
@Dr_AndreRibeiro
#ACR24 – at Washington, DC
Manjari Lahiri retweeted
#ACR24: The year of cell therapy in autoimmune diseases and redefining Tx paradigms!
🧬 Breakfree-1 CD19 CAR-T therapy shows sustained clinical remission in refractory #SLE and a safer profile.
🔬 Next-gen technology on the way. Stay tuned for more!
@Dr_AndreRibeiro – at Washington, DC
Manjari Lahiri retweeted
Sarcoidosis is a granulomatous disorder that affects people of all racial and ethnic backgrounds. The pathogenesis of sarcoidosis remains incompletely understood. Learn more in the latest Interactive Medical Case: nej.md/3UQ4s6V
Clinical year in PREVIEW
Grace Wright @AWIRGROUP
#ACR24
1/3
💥Biomarkers in SLE
Non-invasive urinary panel predicts BOTH active proliferative LN AND response ✅
💥GC sparing in SLE
Disruption of E3-X novel E3-ligase ⬆️GILZ
Clinical year in PREVIEW
Grace Wright @AWIRGROUP
#ACR24
2/3
💥Cell Rx in SLE
💡Autologous anti-CD19 B
💡NEX-T
💡CD3XCD19 TCE
Safety ✅ low CRS, no ICANS, deep depletion
👎🏽infections, neutropenia
Clinical year in PREVIEW
Grace Wright @AWIRGROUP
#ACR24
3/3
💥Anti-obesity meds in RA/ AID
Observational databases (FORWARD - pan-US, community practices)
💪🏽 Improved PRO, APR
👉🏽But ONLY in obese pts
❓⬇️CV risk
New paradigm of combination Rx?
Late breaking L19
Alexei Grom
#ACR24
Emapalumab: anti IFN y Ab, MAS in Still’s dz
💡Data pooled from 2 obs studies, n=49, mostly kids
✅ 1° outcome CR of ALL MAS criteria=53%, 69% if LDH excluded, 82% investigator determined remission, 95% survival
👎🏽TEAE = viral infections🦠
Manjari Lahiri retweeted
✨ Breaking at #ACR24
KN5501 CAR-NK therapy is emerging as a safer and effective alternative to CAR-T for relapsed and refractory SLE patients.
✅ 50% DORIS remission
✅ 68.8% LLDAS (>6 months follow-up)
✅ No Grade ≥2 CRS or ICANS
@Dr_AndreRibeiro – at Washington, DC
Manjari Lahiri retweeted
🔍 Why CAR-NK therapy works?
💥 Deep B-cell depletion + naïve B-cell reset.
💥 Complement normalization (C3, C4).
💥 Anti-dsDNA antibody reduction.
⚠️ Safety First! ⚠️
💡 No severe CRS
💡 No ICANS
💡 No major infections
@Dr_AndreRibeiro – at Washington, DC
Manjari Lahiri retweeted
⁉️ CAR-NK therapy will redefine treatments for lupus ⁉️
✅️ Targeted, very safe immune modulation with off-the-shelf availability.
☢️ As a CAR-T alternative, KN5501 represents a major breakthrough with further studies required to verify this data.
@Dr_AndreRibeiro
#ACR24 – at Washington, DC
Late breaking L17
#ACR24
More excitement in the cellular Rx field!
N=22 refractory lupus
open label (China)
✨CAR-NK (not T)
✨Allogenic!
Avg F/up 7m, max 14m
⬇️ SLEDAI2K, PGA
SRI4 ✅
DORIS remission 6m=50-%, 12m=💯
✨With NO CRS >=2/ ICANS/ infections!
Needs replication!





































